Last reviewed · How we verify
CsA low dose
CsA works by inhibiting calcineurin, a protein phosphatase involved in the activation of T-lymphocytes.
CsA works by inhibiting calcineurin, a protein phosphatase involved in the activation of T-lymphocytes. Used for Prevention of organ rejection in kidney transplant patients.
At a glance
| Generic name | CsA low dose |
|---|---|
| Sponsor | Fovea Pharmaceuticals SA |
| Drug class | calcineurin inhibitor |
| Target | calcineurin |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This inhibition prevents the transcription of interleukin-2 (IL-2), a cytokine that promotes T-cell proliferation. As a result, CsA suppresses the immune response, which is beneficial in preventing organ rejection in transplant patients.
Approved indications
- Prevention of organ rejection in kidney transplant patients
Common side effects
- Nephrotoxicity
- Hypertension
- Diabetes mellitus
Key clinical trials
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (PHASE2)
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (PHASE3)
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) (PHASE3)
- Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
- Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia (PHASE1, PHASE2)
- Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus (EARLY_PHASE1)
- A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CsA low dose CI brief — competitive landscape report
- CsA low dose updates RSS · CI watch RSS
- Fovea Pharmaceuticals SA portfolio CI